

Therapy of Alopecia

This article summarizes the data of the publication "Neue Ansätze in Diagnostik und Therapie der Alopecie in der Gynäkologie" (Therapeutische Umschau, Band 47, 1990, Heft 12) on the efficacy and safety of STPL2-containing hair shampoo and serum in the treatment of female alopecia. The study was conducted at the University Clinic Heidelberg, Department of Gynecology, and Städtische Kliniken Darmstadt, Department of Dermatology.

Alopecia, specifically androgenetic alopecia, used to be treated with systemic medication, e.g. spironolactone, cyproteronacetate, and topical products e.g. minoxidil.

In a clinical trial conducted at the Women's Clinic Heidelberg/Germany, the effect of STPL2-containing topical serum and shampoo (synthetic thymic peptide library) was investigated. A total of 22 female study subjects, solely treated with STPL2-serum and shampoo were observed for 9 to 12 months, four female study subjects were treated with a combination of spironolactone (SPL) plus STPL2, and three study subjects with a combination of STPL2 and the oral contraceptives Diane™ or Neo-Eunomin™.


In an earlier study, 15 females with alopecia were treated with spironolactone, 10 subjects with cyproteronacetate and 10 study subjects with topical minoxidil. Subjects were between 17 and 79 year of age.

Exclusion criteria were endocrine pathologies (e.g. hyperandrogenemia), internal diseases and drug-induced alopecia.

STPL2-containing hair products were used twice daily.

The evaluation criteria for determining treatment efficacy was less than 100 hairs lost per day.

Figure 1. Effectiveness of STPL2 in correlation to duration of therapy



Results:

Already after 6 months of STPL2 treatment, used twice daily, 14 out of 19 study subjects (73%) demonstrated significant improvement in hair loss (Figure 1).

In comparison to earlier studies, spironolactone treated subjects demonstrated efficacy of 33%, cyproteronacetat-treated females 40% and minoxidil-treated subjects 40% (Table 1).

Table 1.
Comparison of different therapies in alopecia

Therapie	Efficacy after 6 months
STPL2	73%(19/26)
Spironolacton	33%(5/15)
Cyproteronacetat	40%(4/10)
Minoxidil	40%(4/10)

Table: 2
Efficacy of STPL2 during 3 to 12 months treatment direction

Efficacy	Treatment duration (months)			
	3	6	9	12
STPL2				
improved	16/22	14/19	10/13	7/8
unchanged	4/22	4/19	1/13	0/8
worse	2/22	1/19	2/13	1/8
STPL2+SPL				
improved	2/4	3/4	2/3	2/3
unchanged	1/4	1/4	1/3	1/3
worse	1/4	0/4	0/3	0/3
SPL				
improved	2/3	2/3	1/2	-
unchanged	0/3	0/3	1/2	-
worse	1/3	1/3	0/2	-

In summary, these data indicate the favorable and superior effects of STPL2 containing shampoo and serum in the treatment of alopecia compared to minoxidil, spironolacton and cyproteronacetat. STPL2 is safe and did not demonstrate any side effects.

References

1. Dauderer M.: Quecksilbervergiftung durch Amalgam. Leitsymptom Kopfschmerzen. Forum des praktischen Arztes und Allgemeinarztes 28, 89, 1989
2. Dauderer M.: Besserung von Nerven und Immunschäden nach Amalgamsanierung. Biologische Medizin 4, 236, 1990.
3. Endres J.-J.: Zur Therapie von Haarausfall unterschiedlicher Genese mit einem östrogen und kortikoidhaltigen Externum. Z. Hautkr. 55 (1), 14, 1980.
4. Imke E., Orfanos C.E. Haarwachstum und Alopezien. Klinikarzt 5, 299, 1988.
5. Lutz G., Kreysel H. W.: Die Bedeutung lymphozytärer Differenzierungsantigene in der Diagnostik und für die Therapie der Alopecia areata. Hautarzt 40, 84, 1989.
6. Moltz L.: Hormonale Diagnostik der sogenannten androgenetischen Alopezie der Frau Geburtsh und Frauenheilk. 48, 203, 1988.
7. Schiele R., Schaller K.H., Weltle D., Mobilisation von Quecksilberspeicherungen im Organismus mittels DMPS (Dimaval), Arbeitsmedizin, Sozialmedizin, Präventivmedizin 11, 249, 1989.
8. Schmidt J.B., Schurz B., Huber J., Spona J., Hypothyreose und Hyperprolaktinämie als mögliche Ursachen der androgenetischen Alopezie der Frau, Z. Hautkr, 64, 9, 1989.
9. Schmidt J. B., Endokrine Konstellation bei der androgenetischen Alopezie der Frau., Wiener Klin. Wochenschr. 99, 21, 1987.
10. Wüstner H., Orfanos C. E.: Alopecia androgenetica und ihre Lokalbehandlung mit östrogen und kortikoidhaltigen Externa Z. Hautkr. 49, 879, 1974.